Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332875 | 0.83 | GABRA2 (0.32) | GABRA2ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL31332813 | 0.72 | NPSR1 (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL13059042 | 0.72 | ADORA2A (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| Hydrochloric Acid SCHEMBL858871 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL31332865 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL31332954 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16427910 | 0.69 | GLP1R (0.38) | GLP1RADORA2ABRD4BRD2BRD3 | |
| SCHEMBL16426889 | 0.69 | GLP1R (0.35) | GABRA2GLP1RADORA2AADORA1PI4KA | |
| SCHEMBL31332988 | 0.68 | GABRB3 (0.32) | GABRA2ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL31332903 | 0.68 | NR4A2 (0.35) | GLP1RBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | GABRA2 354/4885GLP1R 2535/4885ADORA2A 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.